Literature DB >> 3281260

Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria.

J C Sadoff1, W R Ballou, L S Baron, W R Majarian, R N Brey, W T Hockmeyer, J F Young, S J Cryz, J Ou, G H Lowell.   

Abstract

Immunization with radiation-attenuated malaria sporozoites induces potent cellular immune responses, but the target antigens are unknown and have not previously been elicited by subunit vaccines prepared from the circumsporozoite (CS) protein. A method is described here for inducing protective cell-mediated immunity to sporozoites by immunization with attenuated Salmonella typhimurium transformed with the Plasmodium berghei CS gene. These transformants constitutively express CS antigens and, when used to immunize mice orally, colonize the liver, induce antigen-specific cell-mediated immunity, and protect mice against sporozoite challenge in the absence of antisporozoite antibodies. These data indicate that the CS protein contains T cell epitopes capable of inducing protective cell-mediated immunity, and emphasize the importance of proper antigen presentation in generating this response. Analogous, orally administered vaccines against human malaria might be feasible.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281260     DOI: 10.1126/science.3281260

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  63 in total

1.  The cytotoxic T-lymphocyte epitope of the Plasmodium falciparum circumsporozoite protein also modulates the efficiency of receptor-ligand interaction with hepatocytes.

Authors:  D Rathore; T F McCutchan
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria.

Authors:  Lina Wang; Lukasz Kedzierski; Steven L Wesselingh; Ross L Coppel
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

Review 3.  Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens.

Authors:  L Cárdenas; J D Clements
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

Review 4.  Molecular parasitology: progress towards the development of vaccines for malaria, filariasis, and schistosomiasis.

Authors:  S J Cryz
Journal:  Experientia       Date:  1991-02-15

Review 5.  Recombinant avirulent salmonellae as oral vaccine carriers.

Authors:  F Schödel
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

6.  Evidence implicating MHC genes in the immunological nonresponsiveness to the Plasmodium falciparum CS protein.

Authors:  M F Good; S Kumar; A S De Groot; W R Weiss; I A Quakyi; F Dontfraid; G E Smith; M Cochran; J A Berzofsky; L H Miller
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

7.  Antibody responses in the lungs of mice following oral immunization with Salmonella typhimurium aroA and invasive Escherichia coli strains expressing the filamentous hemagglutinin of Bordetella pertussis.

Authors:  C A Guzmán; R M Brownlie; J Kadurugamuwa; M J Walker; K N Timmis
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

8.  Analysis of immunization route-related variation in the immune response to heat-killed Salmonella typhimurium in mice.

Authors:  J Thatte; S Rath; V Bal
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

9.  Immunization of chickens with live Escherichia coli expressing Eimeria acervulina merozoite recombinant antigen induces partial protection against coccidiosis.

Authors:  K S Kim; M C Jenkins; H S Lillehoj
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

10.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

Authors:  S Li; M Rodrigues; D Rodriguez; J R Rodriguez; M Esteban; P Palese; R S Nussenzweig; F Zavala
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.